Valuation: FibroBiologics, Inc.

Market Cap 3.51M 3.09M 2.88M 2.64M 4.95M 336M 5.07M 34.15M 13.36M 166M 13.18M 12.9M 575M P/E 2026 *
-0.66x
P/E 2027 * -0.3x
Enterprise Value 3.51M 3.09M 2.88M 2.64M 4.95M 336M 5.07M 34.15M 13.36M 166M 13.18M 12.9M 575M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.19%
Yield 2026 *
-
Yield 2027 * -
1 day-0.83%
1 week-11.08%
Current month-30.56%
1 month-17.21%
3 months-49.76%
6 months-90.36%
Current year-85.37%
1 week 0.62
Extreme 0.6201
0.75
1 month 0.62
Extreme 0.6201
0.98
Current year 0.62
Extreme 0.6201
9.6
1 year 0.62
Extreme 0.6201
13.16
3 years 0.62
Extreme 0.6201
1,100
5 years 0.62
Extreme 0.6201
1,100
10 years 0.62
Extreme 0.6201
1,100
Manager TitleAgeSince
Chief Executive Officer 62 08/04/2021
Director of Finance/CFO 53 09/06/2025
Chief Tech/Sci/R&D Officer 57 01/08/2021
Director TitleAgeSince
Director/Board Member 60 08/04/2021
Chairman 62 08/04/2021
Director/Board Member 67 08/04/2021
Date Insider Type Main position Quantity % Market Cap.
8/7/26 Other

Director

562 0.0108%
23/6/26 Free

Director

30,803 0.5914%
23/6/26 Free

Director

30,803 0.5914%
Change 5-day change 1-year change 3-year change Capi.($)
-0.83%-11.08%-94.58% - 3.51M
+0.47%+2.27%+50.78%+69.72% 55.01B
+2.83%+0.04%+38.07%+82.59% 54.24B
+1.19%+2.52%-15.55%-13.53% 23.38B
-1.06%-2.03%-0.50%+372.97% 22.57B
+2.07%+1.44%+23.06%-9.05% 20.19B
-2.15%-2.30%+27.27%-33.01% 17.86B
-2.14%-2.72%+30.26%+536.72% 15.5B
-3.14%-8.09%+160.68%+292.18% 14.2B
-2.02%+1.93%+51.71%+184.32% 14.2B
Average -0.45%-2.09%+27.12%+164.77% 23.72B
Weighted average by Cap. +0.36%-0.20%+37.61%+129.58%

Financials

2026 *2027 *
Net sales - -
Net income -20.36M -17.89M -16.7M -15.32M -28.68M -1.95B -29.39M -198M -77.43M -965M -76.43M -74.77M -3.34B -24.01M -21.1M -19.69M -18.07M -33.83M -2.3B -34.67M -234M -91.33M -1.14B -90.15M -88.2M -3.93B
Net Debt - -
Logo FibroBiologics, Inc.
FibroBiologics, Inc. is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 270+ United States and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. Its advanced product candidates are CYWC628, CYPS317, CYMS101 and CybroCell. It has completed its IND-enabling pre-clinical studies for the development of CYWC628 as a topically administered allogeneic fibroblast cell-based therapy for wound healing. CYPS317 is its allogeneic intravenously administered fibroblast spheroid cell-based investigational therapeutic for the treatment of psoriasis. It is developing CYMS101 as an intravenously administered allogeneic fibroblast single cell, and fibroblast spheroid, cell-based therapy to treat multiple sclerosis (MS).
Employees
15
Date Price Change Volume
30/07/26 USD 0.6547 +0.66% 75,419
28/07/26 USD 0.6504 +3.72% 64,178
27/07/26 USD 0.6271 -11.92% 165,490
24/07/26 USD 0.7120 -3.20% 52,376
23/07/26 USD 0.7355 -0.62% 46,587
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.6504USD
Average target price
13.50USD
Spread / Average Target
+1,975.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBLG Stock